Antibody-Drug Conjugates (ADCs): Current Research and Overcoming Challenges

Cancer is one of the leading causes of death worldwide. According to the latest report from the WHO (World Health Organization), cancer accounts for nearly one in six deaths. Antibody-drug conjugates (ADCs) are a relatively new class of anticancer drugs with high specificity and potent killing properties. ADCs consist of three key components: a monoclonal antibody, a linker, and a payload. With the specific antibody targeting the surface antigen of tumor cells, ADCs are internalized and processed by the endo-lysosomal system to release the potent cytotoxic drug. Each of these major components in the development of ADCs may affect efficacy and safety. Additionally, factors such as internalization rate, choice of linkers, and conjugation methods also play a crucial role in the success of ADCs.

DT3C is a recombinant protein mainly used for in vitro evaluation of internalization efficiency of cancer cell towards monoclonal antibodies (mAb), thereby enabling the screening of more effective monoclonal antibodies.

Speaker

Ying Zhou PhD

Product Manager, CUSABIO

Dr. Ying Zhou is a Product Manager at CUSABIO, responsible for product marketing, development, and optimization. Before joining CUSABIO, Dr. Zhou earned her Ph.D. in Biology and Biotechnology from Worcester Polytechnic Institute in the United States. Following her graduation, she pursued post-doctoral training at the University of California, Davis. Dr. Zhou's expertise lies in molecular biology and protein science, specifically in mRNA expression and regulation. She is particularly interested in mRNA stability and RNA-interacting proteins.